Stock-outs and medicine shortages in UK telehealth: how operators actually manage supply disruption

Every operator running dispensing at any real volume eventually hits a stock-out — a manufacturer production delay, a wholesaler allocation cut, or a demand spike nobody modelled. What separates a minor inconvenience from a patient-facing crisis is what happens in the hours after the gap appears: whether there's a lawful substitution route, a second supplier, and a plan to tell patients before they find out at the point of dispatch.

Why supply disruption keeps recurring

Medicine shortages in the UK aren't a rare event confined to a handful of unlucky product lines. Manufacturing has consolidated around a small number of API producers for many generics, import and customs friction adds delay at the border, and demand for some categories — weight management being the obvious recent example — has outpaced production capacity industry-wide. None of this is specific to telehealth, but telehealth operators feel it differently: patients expect delivery windows measured in days, and a silent gap between what a landing page promises and what a dispensing pharmacy can actually source erodes trust fast.

Most operators dispensing a broad formulary will hit at least one significant shortage a year somewhere in their range. The highest-risk lines are usually single-manufacturer generics, anything with a narrow therapeutic index where substitution options are limited, and whatever category is currently in high demand across the whole market rather than just your patient base.

Serious Shortage Protocols: what they change and what they don't

When a shortage becomes severe enough, the Department of Health and Social Care can issue a Serious Shortage Protocol (SSP) for a specific medicine. Where one is in force, a pharmacist dispensing against an NHS prescription can supply a specified alternative — a reduced quantity, a generic equivalent, or a different strength or pack size — without going back to the prescriber first, provided the protocol's exact conditions are met and the substitution is recorded.

The important caveat for most telehealth dispensing: SSPs operate under the NHS pharmaceutical services regulations and apply to NHS prescriptions. Private prescriptions, which is what the bulk of UK telehealth volume runs on, sit outside that mechanism. That means the substitution routes available to a private dispensing pharmacy are typically narrower and rely on protocols agreed with the prescriber in advance, or on going back to the prescriber for a same-day amendment — one more reason prescriber turnaround time matters operationally, not just clinically.

What a pharmacist can and can't substitute

Outside a formal SSP, substitution is governed by ordinary dispensing rules and professional judgement, and the boundaries are narrower than founders sometimes assume. A superintendent pharmacist can typically authorise:

• A different manufacturer's version of the identical generic, same strength and formulation.
• An alternative pack size that reaches the same total prescribed quantity.
• A licensed generic in place of a branded product, where the prescription and clinical picture allow it.

What a pharmacist generally cannot do on their own authority is switch the active ingredient, change the dose form (tablet to capsule, oral to topical), or move to a different strength that changes the dosing regimen — those require prescriber sign-off, or a pre-agreed protocol that covers the specific scenario. Every substitution, whatever the route, gets documented against the patient record with the reason: that record is what a GPhC inspection or an MHRA query will ask to see first.

Telling patients before they notice

The operational failure that turns a shortage into a complaint isn't usually the shortage itself — it's the patient finding out only when their order doesn't arrive. Once a line looks at risk, the dispensing team and the brand's support desk need to be working from the same information at the same time, which means the shortage has to be flagged into whatever system triggers order communications, not just noted in a pharmacy back office.

Good practice is proactive: a message before dispatch explaining the delay or substitution, plain language on what's changed and why, and clear safety-netting on what to do if the patient has concerns about a swapped product. Patients tolerate a delay far better than they tolerate silence, and a substituted product that arrives unexplained reads as a mistake even when it was the correct clinical call.

Forecasting demand to reduce the blast radius

Reactive shortage management catches you after the gap has already opened. The more useful discipline is watching the signals that usually arrive first: wholesaler allocation notices tightening on a line, MHRA and DHSC shortage alerts, and your own order data showing an unexplained volume spike on a SKU that used to be stable. None of these guarantee a shortage is coming, but together they're enough to justify pulling in extra stock or lining up a second source before the shelf actually empties.

This matters most for the categories where a single supply interruption would hit a large share of your patient base — a popular first-line option in a high-volume vertical carries far more operational risk than a niche product with a dozen active patients.

Patients tolerate a delay far better than they tolerate silence — a substituted product that arrives unexplained reads as a mistake even when it was the correct clinical call.

Multi-wholesaler and multi-manufacturer sourcing

The single biggest structural mitigation against stock-outs is not depending on one wholesaler or one manufacturer for a given line. Relationships with two or more wholesalers mean an allocation cut at one doesn't automatically empty the shelf, and where volume justifies it, holding accounts with more than one generic manufacturer for the same molecule spreads the risk further. Building and maintaining those relationships — and holding the wholesale dealer's licence considerations that come with certain sourcing models — is exactly the kind of infrastructure work that's easy to underinvest in until the first serious shortage exposes the gap.

GLP-1 supply in the UK is the sharpest current example of what happens when a whole category runs thin at once, and it's worth reading alongside this piece if weight management is, or will be, part of your formulary.

Where PExpo's dispensing layer fits

PExpo's dispensing partners run on multi-wholesaler sourcing by design, not as a bolt-on fix after the first shortage. When a line is affected, the substitution decision sits with the superintendent pharmacist and is documented against the same records an inspector would ask for — brands aren't left guessing what was swapped or why.

The same infrastructure that handles batch recalls and MHRA Drug Alerts feeds into shortage handling too: the dispensing layer already tracks which patients hold which batch of which line, so a substitution or a recall notice reaches the right patients without a manual audit. If you're weighing clinic dispensing against building this sourcing resilience in-house, that operational overhead is one of the harder costs to estimate upfront — see our pricing for how it's typically structured.

Stock-outs aren't a solved problem anywhere in UK pharmacy, and no operator avoids them entirely. What's controllable is how much damage a given shortage does: whether the substitution pathway is lawful and documented, whether a second wholesaler exists before the first one cuts allocation, and whether patients hear about a gap from you rather than from a missed delivery. See same-day dispensing operations and what dispensing actually involves for the wider operational picture this sits inside.

Frequently asked questions